WHO Technical Report Series, No. 981 - World Health Organization

WHO Expert Committee on Specifications for Pharmaceutical Preparations Forty-seventh report
––
pyrimethamine ICRS;
––
spironolactone ICRS;
■■
the following International Infrared Reference Spectrum (IIRS) for:
––
proguanil hydrochloride IIRS;
■■
and new policies on ICRS for:
––
naming ICRS in The International Pharmacopoeia;
––
analytical testing of high purity candidate material.
The following recommendations were made in the various quality
assurance-related areas. Progress on the suggested actions should be reported to
the Expert Committee on Specifications for Pharmaceutical Preparations at its
next meeting.
Collaboration with and among pharmacopoeias
■■
■■
The Expert Committee expressed recognition and support for WHO's
initiative to work closely with other pharmacopoeias.
It endorsed the development of good pharmacopoeial practices
under the aegis of WHO and the Expert Committee on Specifications
for Pharmaceutical Preparations in collaboration with the world
pharmacopoeias.
The International Pharmacopoeia
WHO Technical Report Series, No. 981, 2013
■■
■■
■■
Continue development of specifications for APIs, medicines, general
methods and texts and general supplementary information in
accordance with the work plan and as decided at this meeting.
Continue the efforts at international collaboration in relation to the
revision and inclusion of specific monographs and general methods.
Continue the preparatory work for a subsequent supplement to The
International Pharmacopoeia, or towards a fifth edition, especially in
electronic form (CD-ROM and online).
International Chemical Reference Substances (ICRS)
■■
■■
Continue promoting the use of International Chemical Reference
Substances (ICRS) through various activities, including a promotional
offer to national authorities.
Continue the efforts to further enhance the development of new ICRS.
40